Eva Carmona Porquera, MD
Pulmonary Disease · Rochester, MNNPI 1427176254
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $15,020 of the $16,610 with a category attached, or 90.4%. Boehringer Ingelheim accounts for 99.9% of it on its own, with 1 other manufacturer making up the rest. Among pulmonary disease clinicians in MN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 10 payments — averaging $1660.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$17K
- Philips North America LLC$22
Across 35 payments — averaging $5471.03 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Roche Products Limited$157K
- Biogen$35K
What the payments were for
- Consulting fees$15,02090%
- Travel & lodging$1,3218%
- Food & beverage$2682%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 9 | $16,588 |
| Philips North America LLC | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OFEV$11,241
How this compares
$16,610 in reported general payments places this provider in the 90th percentile of 261 pulmonary disease providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 33 | $395,464 |
| Mycophenolate Mofetil | 12 | $897 |
| Prednisone | 21 | $120 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 14 | $112 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev | $16,588 | $395,46433 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 261 pulmonary disease providers in Minnesota.
Other pulmonary disease in Rochester
- Hilary DubrockRochester$102K
- Ulrich SpecksRochester$77K
- Jagdeep BijwadiaRochester$54K
- Teng MouaRochester$47K
- Timothy AksamitRochester$26K
- Michael KrowkaRochester$25K
- Kaiser LimRochester$18K
- Robert VassalloRochester$18K
- Tobias PeikertRochester$10K
- Joseph SkalskiRochester$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.